随机临床试验:普瑞巴林对比安慰剂治疗肠易激综合征
一项双盲安慰剂对照试验将85例符合罗马III标准且每月腹痛发作≥3次的成人肠易激综合征患者随机分入普瑞巴林225 mg组或安慰剂组,每日两次,治疗12周。第9-12周平均腹痛肠道症状量表评分普瑞巴林组低于安慰剂组(25 vs 42,P=0.008),总体肠道症状量表严重度评分也较低(26 vs 42,P=0.009),腹泻和腹胀评分差异有统计学意义,便秘评分无差异,两组充分缓解率无显著差异(46% vs 36%,P=0.35)。该试验提示普瑞巴林可能对肠易激综合征腹痛、腹胀和腹泻有益。
要点
- 普瑞巴林225 mg每日两次治疗12周后,第9-12周平均腹痛肠道症状量表评分低于安慰剂组(25 vs 42,P=0.008)。
- 普瑞巴林组总体肠道症状量表严重度评分低于安慰剂组(26 vs 42,P=0.009),腹泻和腹胀评分差异有统计学意义。
- 两组充分缓解率无显著差异(普瑞巴林46% vs 安慰剂36%,P=0.35),便秘评分无差异。
核心结论
- 该试验提示普瑞巴林可能对肠易激综合征腹痛、腹胀和腹泻有益。
研究设计与样本
- 双盲、安慰剂对照试验,纳入符合罗马III标准且每月腹痛发作≥3次的成人肠易激综合征患者85例。
- 患者随机接受普瑞巴林225 mg或安慰剂每日两次,治疗12周,每周完成问卷。
- 主要终点为第9-12周平均腹痛肠道症状量表评分,采用意向性分析协方差分析调整年龄和性别。
主要发现
- 普瑞巴林组第9-12周平均腹痛肠道症状量表评分低于安慰剂组(25 vs 42,P=0.008)。
- 普瑞巴林组总体肠道症状量表严重度评分低于安慰剂组(26 vs 42,P=0.009)。
- 腹泻肠道症状量表评分(P=0.049)和腹胀肠道症状量表评分(P=0.016)组间差异有统计学意义,便秘肠道症状量表评分无差异。
- 两组充分缓解率无显著差异(普瑞巴林46% vs 安慰剂36%,P=0.35)。
- 第12周较基线疼痛评分变化≥30的比例普瑞巴林组63% vs 安慰剂组45%(P=0.10),治疗后肠易激综合征生活质量评分两组无差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregabalin is a calcium channel α2δ ligand that modifies visceral hypersensitivity in IBS patients. Clinical data for pregabalin in IBS are lacking. AIM: To test the efficacy of pregabalin on gastrointestinal symptoms in IBS patients. METHODS: A double-blind, placebo-controlled trial was performed. Adults meeting IBS Rome III criteria with ≥3 pain attacks per month were randomised to pregabalin 225 mg vs placebo twice daily for 12 weeks. Questionnaires were completed weekly. The primary endpoint was average pain Bowel Symptom Scale (BSS) scores weeks 9-12. An intention-to-treat analysis of covariance evaluated treatment effects on quantitative endpoints, adjusting for age and gender. Adequate relief and change in pain score were assessed using a chi-squared test. RESULTS: Eighty-five patients were recruited and randomised. Sample characteristics include: mean age 39.4 (SD = 14.6); 73 (86%) female; 37 (44%) IBS-D, 29 (35%) IBS-M, 18 (21%) IBS-C. The pregabalin arm had lower average pain-BSS scores weeks 9-12 (25 vs 42, P = 0.008). Compared with placebo, the overall IBS BSS severity score was lower in the pregabalin arm (26 vs 42, P = 0.009). Differences were observed for the diarrhoea-BSS and bloating-BSS scores (P = 0.049 and 0.016, respectively). No differences between groups were seen for constipation-BSS scores. Adequate relief was not different between the two arms (46% vs 36%, P = 0.35). 63% pregabalin vs 45% placebo had a change in pain score ≥30 at week 12 from baseline (P = 0.10). Post-treatment IBS-QoL scores did not differ between groups. CONCLUSION: This trial suggests that pregabalin may be beneficial for IBS abdominal pain, bloating and diarrhoea.
引用
- Saito YA, Almazar AE, Tilkes KE, et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther. 2019. PMID: 30663077. doi:10.1111/apt.15077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。